Leflunomide Aspire Pharma

Leflunomide, the active ingredient in Leflunomide Aspire Pharma, is an immunomodulatory agent presented as a tablet for oral use. It is indicated for the treatment of rheumatoid arthritis and psoriatic arthritis in adult patients. The medication is formulated to provide consistent systemic exposure, supporting long‑term disease control.

GNH USA supplies Leflunomide Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics for global markets.

Leflunomide is a disease-modifying antirheumatic drug that modulates immune activity in inflammatory arthritis.

Rheumatoid arthritis: reduces joint inflammation, pain, and slows structural damage. Psoriatic arthritis: improves skin lesions and joint symptoms, helping to control disease activity.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Headache: occasional tension‑type headaches. - Hypertension: elevation of blood pressure.

Serious or Rare Side Effects: - Hepatotoxicity: significant increase in liver enzymes or liver injury. - Severe infection: increased susceptibility to bacterial, viral or fungal infections. - Aplastic anemia or pancytopenia: rare bone‑marrow suppression.

When prescribing Leflunomide, clinicians should observe several precautionary measures to minimize risk.

- Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential. - Liver function: obtain baseline tests and monitor periodically for hepatotoxicity. - Blood pressure: monitor regularly as hypertension may develop. - Infection risk: assess for active infections before initiating therapy. - Vaccination: avoid live vaccines during treatment. - Store at ambient temperature: keep in the original packaging, protect from moisture.

Leflunomide can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Teriflunomide: additive toxicity due to shared metabolic pathways. - Methotrexate: increased risk of hepatotoxicity and bone‑marrow suppression. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may raise Leflunomide plasma levels.

Moderate Interactions (Monitor Closely): - Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring. - Live vaccines: reduced effectiveness, consider timing of vaccination. - Statins: possible increased risk of myopathy, monitor muscle symptoms.